Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_assertion type Assertion NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_head.
- NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_assertion description "[Although H&H combination treatment (high active TIL and high sensitive drugs) as previously described to solid tumor patients is more efficient than single-agent treatments such as TIL adoptive immunotherapy, it has a short-term efficiency for the immune response to metastatic cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_provenance.
- NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_assertion evidence source_evidence_literature NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_provenance.
- NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_assertion SIO_000772 10654199 NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_provenance.
- NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_assertion wasDerivedFrom befree-20140225 NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_provenance.
- NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_assertion wasGeneratedBy ECO_0000203 NP789506.RA3Xh4Su-hWU6gQi11bJ9b1FauHNHb8Y_MLQrlYq58HPQ130_provenance.